Resverlogix Announces Participation at the Upcoming Global Chinese Financial Forum (“GCFF”) Virtual Conference 2020 – Investing in Innovation

https://www.resverlogix.com/investors/news.html?article=674

CALGARY, Alberta, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announces its participation at the GCFF Virtual Conference 2020 - Investing in Innovation (“GCFF Virtual Conference”) on September 10, 2020. Donald McCaffrey, the Company’s President and CEO, will provide a live video presentation commencing at 10:35 am PST / 1:35 pm EST.

About the GCFF Virtual Conference 2020 - Investing in Innovation

Registration for the GCFF Virtual Conference is complimentary and recommended to be made in advance by using the link HERE. Registration will close one day before the event.

The GCFF Virtual Conference, held on September 10, 2020, will connect Chinese investors living throughout North America to the latest investment opportunities in the fast growing innovative sectors of healthcare, life science, technology, clean technology, fintech and cannabis.  Hosted by NAI Interactive Ltd., the bilingual online event will feature public and private company investment opportunities and will be broadcast in English and Mandarin Chinese.

An archived link to the presentation will be made available approximately one week after the live event on the Company website HERE.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. Apabetalone is the first therapy of its kind to have been granted US FDA Breakthrough Therapy Designation – for a major cardiovascular indication – to help facilitate a time-efficient drug development program including planned clinical trials and plans for expediting the manufacturing development strategy.

BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on:

• Twitter: @Resverlogix_RVX
• LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/

For further information please contact:

Investor Relations
Email: [email protected]
Phone: 403-254-9252
Or visit our website: www.resverlogix.com